Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 11, 2023HaematologicaOpen Access

Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial

View Full Paper
Ask AI
Bookmark
Share

Authors

SVSrđan VerstovšekLFLynda FoltzVGVikas Gupta

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Verstovšek et al. (2023) studied this question.

synapsesocial.com/papers/6a1e6db574572fec71952a8ahttps://doi.org/10.3324/haematol.2022.282411
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pentraxin-2 suppresses c-Jun/AP-1 signaling to inhibit progressive fibrotic disease2016 · 60 citations
  2. 2Myeloproliferative neoplasm stem cells2017 · 188 citations
  3. 3Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis2016 · 517 citations
  4. 4Serum Amyloid P Therapeutically Attenuates Murine Bleomycin-Induced Pulmonary Fibrosis via Its Effects on Macrophages2010 · 195 citations
  5. 5Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor2016 · 128 citations